Evaluating, Testing and Advancing Oncology Therapies

Last Modified: December 3, 2004

Share article


Conference Dates: February 9-11, 2005
Conference Location: Philadelphia, PA

Sponsoring Group: ExL Pharma

Conference Web Page URL: http://www.exlpharma.com/events/p301/index.php

Topics Covered: ExL Pharma is proud to present Evaluating, Testing and Advancing Oncology Therapies, focusing on Trial Design, Testing Strategies, and Clinical Development Planning. Hear from Industry experts on the most pressing issues pharma and biotech face when conceiving, developing, and conducting their oncology clinical trials. Join thought-leaders and your fellow industry colleagues at this comprehensive industry event

Information: To register please visit www.exlpharma.com or call 866-247-9597

Conference Fees: $1795 conference and workshop and $1495 for conference only (IF registered by January 7, 2005). After January 7, 2005, $1995 for conference and workshop and $1695 for conference only

Continuing Education: No


News
CA-125 blood test, transvaginal ultrasound do not lower risk, have high false-positive rate

May 23, 2011 - The combined use of a CA-125 blood test and transvaginal ultrasound for early detection of ovarian cancer does not appear to reduce the risk of death from the disease in the general population, and harm may result from diagnostic evaluation performed after false-positive tests, according to research to be presented at the annual meeting of the American Society of Clinical Oncology, held from June 3 to 7 in Chicago.



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More